Background

The Endeavor (Medtronic) zotarolimus-eluting stent (ZES) has shown favorable results in reducing target lesion revascularization (TLR) and vessel failure (TVF) in several registries and randomized trials. We report our experience with ZES in a series of patients at our medical center with 2-year follow-up.

Methods

Data on 235 consecutive patients stented with ZES were retrospectively analyzed. The primary endpoint of the study was TVF defined as the combined endpoint of cardiac death, nonfatal myocardial infarction and TLR. Secondary endpoints included TLR, target vessel revascularization (TVR), acute stent thrombosis (ST) as defined by the academic research consortium (ARC), total death and nonfatal myocardial infarction (MI). The angiograms of the first 158 consecutive patients were reviewed by an independent cardiologist, and SYNTAX scoring was performed. Follow-up was achieved using medical records and/or phone calls at a mean of 655 days. Descriptive analysis was performed on all variables.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Coronary stenting with MGuard: extended follow-up of first human trial
2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
3. Treatment of STEMI with neither PCI nor thrombolysis
4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree